MAPT and Alzheimer disease: These articles on biomarker discoveries highlight the deep phenotyping available in the EPAD LCS and demonstrate some important emerging findings, particularly around the effects on cognition of tau in participants without dementia and the need to expand beyond amyloid when considering the multifactorial risk factors for AD.